● Leading multiple projects in Oncology to develop NGS based end-to-end clinical solutions that bring mid-long term commercial revenue opportunity. ● Gathering Market Intelligence by thorough Market research speaking to Key Opinion leaders and Health Care Professionals.● Liaising with internal development teams to build a clinical product based on unmet market needs.● Working with the marketing and commercial team to develop a go to market strategy.● Establishing Research Collaborations and building strategic partnerships with external institutions and companies to develop end to end clinical assays and building path forward to IVD products.

● Managed R&D projects to improve nanopore platform making it robust and stable for production and sales.

● Lead multiple projects to improve Oxford Nanopore sequencing chemistry and significantly improved DNA single read accuracy to >99% (Q20).● Line managed 2 people and recruited 4 people as a part of building a strong successful team.● Generated 8 patents for the company.

Improving the accuracy and throughput of current ONT nanopore chemistry (R9 series)Involved in meeting stakeholders to transfer the product from Research to Development (following to production)Started Line management of interns and student visiting ONT

● Protein engineering for optimization of membrane proteins for DNA sequencing.● Collaborating with multiple internal departments to optimize the chemistry.● Expression, purification, electrophysiology testing and data analysis of designed protein nanopores to improve the performance of Oxford Nanopore sequencers by improving throughput, accuracy, and stability.

-Single channel Electrophysiology of ion-channels-Transport of Solutes through the Outer-membrane channels of Gram-positive and Gram-negative bacteria.-Collaboration with major companies and academic institution for the European IMI Program "New Drugs for Bad Bug"

Biotechnology lab I and II

Genetic Engineering of FtsK protein, a DNA motor protein